Nuvation Bio, Inc. (NUVB)
| Market Cap | 750.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -87.74M |
| Shares Out | 218.13M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 632,131 |
| Open | 3.52 |
| Previous Close | 3.55 |
| Day's Range | 3.43 - 3.60 |
| 52-Week Range | 3.25 - 10.45 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 14.96 (+334.9%) |
| Earnings Date | Aug 11, 2022 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an ad... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for NUVB stock is "Buy." The 12-month stock price forecast is 14.96, which is an increase of 334.88% from the latest price.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
NEW YORK , June 28, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB). Such investors are advised to conta...
FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why
The FDA has placed a partial clinical hold on Nuvation Bio Inc's (NYSE: NUVB) Phase 1 dose-escalation study of NUV-422 in solid tumors. The company's Phase 1 trial began enrolling patients in December 2...
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates...
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates...
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates...
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumors. NUV-868 inhibits BRD4, a key member of the BET famil...
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advance...
NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeut...
Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones
David Hung, M.D., founder, president, and chief executive officer, to present virtually at the 40th Annual J.P.
Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Gliob...
NEW YORK, Dec. 15, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeut...
Why Nuvation Bio Shares Are Rising
Nuvation Bio Inc (NYSE:NUVB) shares are trading higher after the company announced FDA clearance of its investigational new drug application for NUV-422. "FDA clearance of our third IND application for ...
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostat...
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeut...
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advance...
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...
Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeut...
Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeut...
Nuvation Bio Appoints David C. Hanley, Ph.D.
NEW YORK, June 1, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...
Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference
NEW YORK, May 26, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...
David Abrams Buys 3 Stocks in 1st Quarter
David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, disclosed his first-quarter portfolio earlier this month.
Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update
NEW YORK, May 17, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...
Panacea Acquisition Corp. II Announces Pricing of $150,000,000 Initial Public Offering
SAN FRANCISCO, CA, April 06, 2021 (GLOBE NEWSWIRE) -- Panacea Acquisition Corp. II (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition,...
Panacea Announces Effectiveness of Registration Statement for Proposed Business Combination with Nuvation Bio
SAN FRANCISCO--(BUSINESS WIRE)--Panacea Acquisition Corp., a Delaware corporation (the “Company”) (NYSE: PANA.U, PANA, PANA WS), announced today that its registration statement on Form S-4 (File No. 333...
4 SPAC Mergers: What The KBLM, ACAM, PANA And SMMC Deals Mean For Investors
Last week saw continued momentum in special purpose acquisition company (SPAC) mergers, as KBL Merger (NASDAQ: KBLM), Acamar Partners Acquisition Corp. (NASDAQ: ACAM), Panacea Acquisition Corp. (NYSE: P...